Muscle high-energy metabolites and metabolic capacity in patients with heart failure.
OKITA, K., K. YONEZAWA, H. NISHIJIMA, A. HANADA, T. NAGAI, T. MURAKAMI, and A. KITABATAKE. Muscle high-energy metabolites and metabolic capacity in patients with heart failure. Med Sci. Sports. Exerc., Vol. 33, No. 3, 2001, pp. 442-448.


BACKGROUND
Various abnormalities in skeletal muscle have been demonstrated by biopsy in patients with chronic heart failure (CHF). In mammalian muscles, high-energy metabolite composition at rest (HEMC) provides data on important metabolic characteristics; however, the significance of HEMC has not been clarified in patients with CHF. Therefore, we investigated HEMC in normal subjects and patients with CHF and examined its relation to muscle metabolic capacity and exercise tolerance.


METHODS
High-energy metabolites (phosphocreatine (PCr), inorganic phosphate (Pi), and ATP) in resting calf muscle were measured by 31P-magnetic resonance spectroscopy (31P-MRS), and ratios of Pi to PCr, Pi to ATP, and PCr to ATP were calculated in 34 patients with CHF and 13 age- and size-matched normal subjects. Muscle metabolism was evaluated during local exercise of unilateral plantar flexion by 31P-MRS. Metabolic capacity was estimated by the rate of PCr breakdown in relation to the workload. Systemic exercise capacity was evaluated by a bicycle ergometer.


RESULTS
The ratio of PCr to ATP was significantly increased in patients with CHF compared with controls (3.06 +/- 0.43 vs 2.72 +/- 0.36, P < 0.05) and was significantly correlated with metabolic capacity (r = -0.37, P < 0.01) and with peak oxygen uptake (r = -0.45, P < 0.01). There was a significant correlation between metabolic capacity and peak oxygen uptake (r = 0.53, P < 0.001).


CONCLUSIONS
HEMC was altered in patients with CHF, and this change was related to metabolic capacity and exercise capacity. These findings provide new insight into the mechanism of impaired muscle metabolism in CHF.
Okita
K
K
Department of Cardiovascular Medicine, Hokkaido University School of Medicine, Sapporo 060-8638, Japan. cvext@med.hokudai.ac.jp
Yonezawa
K
K
Nishijima
H
H
Hanada
A
A
Nagai
T
T
Murakami
T
T
Kitabatake
A
A
D000255:Adenosine Triphosphate / Q000378:metabolism; D000368:Aged; D015444:Exercise / Q000502:physiology*; D005260:Female; D006333:Heart Failure / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000502:physiology*; D010101:Oxygen Consumption; D010710:Phosphates / Q000378:metabolism; D010725:Phosphocreatine / Q000032:analysis* / Q000378:metabolism; D010809:Physical Fitness
D010710:Phosphates; D010725:Phosphocreatine; D000255:Adenosine Triphosphate